SIEMENS HEALTHCARE DIAGNOSTICS, INC. ATELLICA IM SARS-COV-2 TOTAL (COV2T); SARS-COV-2 TOTAL IMMUNOASSAY
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Negative Result (1225)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 02/18/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
An outside of the united states (ous) customer contacted the siemens customer care center (ccc) to report discordant, non-reactive atellica im sars-cov-2 total (cov2t) results obtained from two samples that were considered discordant compared to testing with a different lot of atellica im sars-cov-2 total and an alternate method.Qc was in range at the time of testing.The interpretation of results section of the instructions for use (ifu) states: "the system reports advia centaur cov2t assay results in index values or u/ml and as non-reactive or reactive: non-reactive: < 1.00 index (u/ml).These samples are considered negative for sars-cov-2 antibodies.Reactive: =1.00 index (u/ml).These samples are considered positive for sars-cov-2 antibodies." the calculation of results section of the ifu states: "conversion formula: 1.00 index value = 1.00 u/ml" the limitations sections of the ifu state: "results are not intended to be used as the sole basis for patient management decisions.Test results should be interpreted in conjunction with clinical observations, patient history, epidemiological information, and other laboratory findings." "a non-reactive test result does not exclude the possibility of exposure to or infection with sars-cov-2.Patient specimens may be non-reactive if collected during the early (preseroconversion) phase of illness or due to a decline in titer over time.In addition, the immune response may be depressed in elderly, immunocompromised, or immunosuppressed patients." be non-reactive if collected during the early (preseroconversion) phase of illness or due to a decline in titer over time.In addition, the immune response may be depressed in elderly, immunocompromised, or immunosuppressed patients." a false negative/non-reactive result would be correlated with clinical history and presentation and may lead to additional testing and/or continued precautions to avoid infection with negligible clinical impact.Although there is no potential for serious injury in this case, an mdr will be reported to the fda as a requirement of the emergency use authorization (eua).Siemens healthcare diagnostics is investigating.
|
|
Event Description
|
The customer reported atellica im sars-cov-2 total (cov2t) non-reactive (negative) results were obtained from two samples and the results were considered discordant compared to testing with a different lot of atellica im sars-cov-2 total and an alternate method.It is unknown if the non-reactive results were reported to the physician(s).There are no reports that treatment was altered or prescribed or adverse health consequences due to the discordant, non-reactive atellica im sars-cov-2 total (cov2t) results.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2022-00087 on march 18, 2022.March 24, 2022, additional information: an outside of the united states (ous) customer contacted the siemens customer care center (ccc) to report discordant, nonreactive atellica im sars-cov-2 total (cov2t) results obtained from two samples that were considered discordant compared to testing with a different lot of atellica im sars-cov-2 total and an alternate method.Siemens healthcare diagnostics has completed the investigation into alleged difference in cov2t results between lot 012 and 013.Quality control and calibrations were appropriate for both kit lots at the time of testing.In review of in-house data, there is no data that showed patients positive on lot 12 but negative on lot 13.No patient history was available, and no further testing could be conducted as the kit lot 012 had expired.This appears to be a sample-specific issue however without further medical history siemens healthcare is unable to determine root cause.It was agreed with the customer to save samples and will rerun a method comparison when this kit is close to expiry with the new kit.The root cause could not be determined.No product nonconformance was identified.In section h6, the investigation finding, and investigation conclusion codes were updated.
|
|
Search Alerts/Recalls
|
|
|